Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.
-
Xiang JC, Xia ZY, Sun JX, Ye GC, Wang Y, Yang J, Wang SG, Xia QD. First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer. J Immunother Cancer. 2026 May 13; 14(5).
-
Xia QD, Xu MY, Zhu XH, Yang J, Wang SG. PSMA PET/MRI-US Fusion-Guided Irreversible Electroporation for Focal Therapy of Prostate Cancer. Clin Nucl Med. 2026 Aug 01; 51(8):661-663.
-
Zhou L, DeMarco KD, Murphy KC, Wu Z, Li J, Johnson C, Liu B, Giwa HK, Ma B, Bhalerao N, Li J, Jiang Z, Bai S, Parikh CN, Ye T, Simin K, Zhu LJ, Pitarresi JR, Wu H, Ruscetti M. p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. Cancer Discov. 2026 Mar 02; 16(3):571-591.
-
Ortner G, Hoderlein X, Barbato F, Beyersdorff D, Bud?us L, Burger IA, Eiber M, Graefen M, Hadaschik B, Haese A, Herrmann K, Maack L, Maric I, Mattei A, Rauscher I, Salomon G, Sauer M, Schimm?ller L, Schlaefer A, Schlemmer HP, Spohn SKB, Umutlu L, Walz J, W?rnschimmel C, Koehler D, Maurer T. The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer. J Nucl Med. 2026 01 02; 67(1):154-159.
-
Fonteyne V, Tree A, Castro E, Touijer K, Walz J. Prostate cancer. Lancet. 2026 Feb 07; 407(10528):622-636.
-
Sun JX, Ma SY, Xu JY, Abudureyimu M, An Y, Xu JZ, Zhang SH, Zhang ZY, Guo CX, Liu BL, Wang SG, Xia QD. Escherichia coli Nissle 1917 outer membrane vesicles encapsulating oncolytic virus remodel tumor-associated macrophages and kill prostate cancer cells. J Control Release. 2026 02 10; 390:114514.
-
Ma F, Chen S, Cecchi L, Ersoy-Fazlioglu B, Russo JW, Arai S, Awad S, Calagua C, Xie F, Poluben L, Voznesensky O, Ku AT, Karzai F, Cai C, Einstein DJ, Ye H, Yuan X, Toker A, Taplin ME, Sowalsky AG, Balk SP. Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion. J Clin Invest. 2025 12 01; 135(23).
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Lee D, Jeon KH, Jung J, Han K, Cho MH, Cho IY, Shin DW. Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study. Rheumatology (Oxford). 2025 06 01; 64(6):3458-3467.
-
De La Cerda J, Belkoff L, Courtney KD, Diamond E, D'Olimpio J, Dunshee C, Gervasi L, Goodman M, Mittal K, Morris D, Sieber P, Tutrone R, Ryan M, Zhong Y, Ufer M, Shore N. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial. Target Oncol. 2025 May; 20(3):503-517.